A compartmental absorption and transit model for estimating oral drug absorption

International Journal of Pharmaceutics

Volumn 186, Issue 2, 1999, Pages 119-125

  Yu, Lawrence X ^a   Amidon, Gordon L ^b  

^a GLAXOSMITHKLINE   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Compartmental modeling; Drug absorption kinetics; Fraction of dose absorbed; Permeability

Indexed keywords

ATENOLOL; ENALAPRILAT; FLUINDOSTATIN; FUROSEMIDE; KETOPROFEN; METOPROLOL; NAPROXEN; PHENAZONE; PROPRANOLOL; TERBUTALINE;

ARTICLE; COMPARTMENT MODEL; COMPUTER SIMULATION; DRUG ABSORPTION; DRUG DETERMINATION; INTESTINE ABSORPTION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; STATISTICAL ANALYSIS;

NON-PROGRAMMATIC;

ADSORPTION; ALGORITHMS; COMPUTER SIMULATION; DIGESTIVE SYSTEM; GASTRIC EMPTYING; HUMANS; MODELS, BIOLOGICAL; MODELS, CHEMICAL; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; STOMACH;

EID: 0032888376     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5173(99)00147-7     Document Type: Article

References (26)

1. American Hospital Formulary Service. 1998 Edition, pp. 1982.
2. Amidon G.L., Lennernas H., Shah V.P., Crison J.R. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 12:1995;413-420.
3. Amidon, G.L., 1996. Unpublished results.
4. Benet L.Z., (ie S., Schwartz J.B. Design and optimization of dosage regiments; pharmacokinetic data. Hardman J.G., Limbird L.E., Gilman A.G. The Pharmacological Basis of Therapeutics. 9th edition:1996;1707-1793 McGraw-Hill, New York.
5. Clements J.A., Heading R.C., Nimmo W.S., Prescott L.F. Kinetics of acetaminophen absorption and gastric emptying in man. Clin. Pharmacol. Ther. 24:1978;420-431.
6. D'Argenio, D.Z., Schumitzky, A. 1992. Adapt II: Mathematical Software for Pharmacokinetics/Pharmacodynamics Systems Analysis, University of Southern California, Los Angles.
7. Davies D.S. Pharmacokinetics of terbutaline after oral administration. Eur. J. Resp. Dis. Suppl. 134:1984;111-117.
8. Dressman J.B., Fleisher D., Amidon G.L. Physicochemical model for dose-dependent drug absorption. J. Pharm. Sci. 73:1984;1274-1279.
9. Eichelbaum E., Ochs H.R., Roberts G., Somogyi A. Pharmacokinetics and metabolism of antipyrine after intravenous and oral administration. Arzneim-Forsch. 32:1982;575-578.
10. Fagerholm U., Borgstrom L., Ahrenstedt O., Lennernas H. The influence of net water absorption on the small intestinal permeability of terbutaline, studied in vivo in man. J. Drug Target. 3:1995;191-200.
11. Ho N.F.H., Park J.Y., No P.F., Higuchi W.I. Advanced quantitative and mechanistic approaches in interfacing gastrointestinal drug absorption studies in animals and humans. Crouthanel W., Sarapu A.C. Animal Models for Oral Drug Delivery in Man: In Situ and In Vivo Approaches. 1983;27-106 American Pharmaceutical Association, Washington, DC.
12. Kubo S.H., Cody R.J. Clinical pharmacokinetics of the angiotensin converting enzyme inhibitors. Clin. Pharmacokinet. 10:1985;377-391.
13. Lennernas H., Ahrenstedt O., Hallgren R., Knutson L., Ryde M., Paalzow L.K. Regional jejunal perfusion, a new in vivo approach to study oral drug absorption in man. Pharm. Res. 9:1992;1243-1251.
14. Lennernas H., Ahrenstedt O., Ungel A.-L. Intestinal drug absorption during induced net water absorption in man: A mechanistic study using antipyrine, atenolol and enalaprilat. Br. J. Clin. Pharmacol. 37:1994;589-596.
15. Lennernas, H., Knutson, L., Knutson, T., Lesko, L., Salmonson, T., G.L. Amidon, G.L. 1995. Human effective permeability data for furosemide, hydrochlortiazide, ketoprofen, and naproxen to be used in the proposed biopharmaceutical classification for IR-products. Pharm. Res. 12, S396.
16. Lindahl A., Sandstrom R., Ungell A.-L., Knutsson L., Abrahamsson B., Lennernas H.A. Human study of the regional jejunal effective permeability of fluvastatin, atenolol, metoprolol, and antipyrine. Pharm. Res. 12:1995;S295.
17. Mason W.D., Winer N., Kochak G., Cohen I., Bell R. Kinetics and absolute bioavailability of atenolol. Clin. Pharmacol. Ther. 25:1979;408-415.
18. Paterson J.W., Conolly M.E., Dollery C.T., Hayes A., Cooper R.G. The pharmacodynamics and metabolism of propranolol in man. Pharmacol. Clin. 2:1970;127-133.
19. Ponto L.L.B., Schoenwald R.D. Furosemide: a pharmacokinetics/pharmacodynamic review. Clin. Pharmacokinet. 18:1993;381-408.
20. Riddell J.G., Harron D.W.G., Shanks R.G. Clinical pharmacokinetics of β-adrenoceptor antagonists. Clin. Pharmacokinet. 12:1987;305-320.
21. Sinko P.J., Leesman G.D., Amidon G.L. Predicting fraction dose absorbed in humans using a macroscopic mass balance approach. Pharm. Res. 8:1991;979-988.
22. Tse F.L.S., Jaffe J.M., Troendle A. Pharmacokinetics of fluvastatin after single and multiple doses in normal volunteers. J. Clin. Pharmacol. 32:1992;630-638.
23. Wagner, J.G. 1993. Pharmacokinetics for the Pharmacokinetical Scientists; Technomic Publishing, Inc. pp. 45-50.
24. Yu L.X., Crison J.R., Amidon G.L. Transport approaches to the biopharmaceutical design of oral drug delivery systems: prediction of oral drug absorption. Adv. Drug Del. Rev. 19:1996;359-376.
25. Yu L.X., Crison J.R., Amidon G.L. Compartmental transit and dispersion model analysis of small intestinal transit flow in humans. Int. J. Pharm. 140:1996;111-118.
26. Yu L.X., Amidon G.L. Characterization of small intestinal transit time distribution in humans. Int. J. Pharm. 171:1998;157-163.